Metaphore Biotechnologies
A Flagship-founded biotech designing novel therapeutics by combining machine learning and molecular mimicry.
The company was launched in May 2023, with Flagship making an initial commitment of $50 million to advance Metaphore’s MIMiC platform and build its pipeline for patients with autoimmune, metabolic, or oncology indications. The MIMiC platform is a computationally driven bioplatform designing new therapeutics where function, specificity, and selectivity can be optimized.
Latest Metaphore Biotechnologies News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze